Scientists probe tumor immune cells in bone cancer patients treated with mifamurtide
NCT ID NCT03737435
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study examined stored tumor samples from 80 people with localized osteosarcoma who received chemotherapy with or without the drug mifamurtide. Researchers analyzed the immune cells and genes inside the tumors to see how the tumor environment relates to patient survival. The goal is to better understand why some patients respond better to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mifamurtide
- What this could lead to
- If successful, this could help doctors understand which patients with osteosarcoma might benefit most from adding mifamurtide to chemotherapy.
- What could go wrong
- This is a retrospective biological study, not a treatment trial. It only looks at stored tumor samples, so it cannot prove that mifamurtide works better or causes harm.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALIZED OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
SSD Chemioterapia dei tumori dell'apparato locomotore
Bologna, 40136, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.